Clinical Efficacy and Adverse Reactions of Bevacizumab plus Radiochemotherapy in the Treatment of Advanced Gastric Cancer

Table 1

Comparison of general data between the two groups of patients.

Indexes	Research group (n = 43)	Control group (n = 43)	t/χ^2
Age (year, )	54.38 ± 3.52	55.12 ± 3.57	0.968	0.336
KPS scores (points, )	68.94 ± 2.13	69.13 ± 2.15	0.412	0.682
Course of disease (year, )	5.47 ± 2.32	5.54 ± 2.34	0.139	0.890
Gender (n/%)			0.189	0.664
Male	23	25
Female	20	18
TNM stage (n/%)			0.199	0.655
IIIb	26	28
IV	17	15
Pathological type (n/%)			0.272	0.873
Mucinous carcinoma	7	8
Indolent cell carcinoma	3	4
Adenocarcinoma	33	31
Differentiation (n/%)			0.455	0.929
Undifferentiated	8	7
Lowly differentiated	13	11
Moderately differentiated	12	13
Highly differentiated	10	12

KPS, Karnofsky performance score (KPS); TNM, tumor node metastasis.